Frederick Lombard, DO
Family Medicine · Williamsport, PANPI 1952830234
Payments from drug & device makers
Across 155 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$359
- GSK$353
- AstraZeneca$312
- Lilly USA, LLC$303
- Novo Nordisk$295
- Exact Sciences$132
- plus $987 from 25 others
What the payments were for
- Food & beverage$2,741100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 22 | $359 |
| GSK | 22 | $353 |
| AstraZeneca(2 entities) | 14 | $312 |
| Lilly USA, LLC | 18 | $303 |
| Novo Nordisk | 17 | $295 |
| Exact Sciences | 5 | $132 |
| Amgen | 7 | $101 |
| Indivior Inc. | 5 | $97 |
| Pfizer | 6 | $93 |
| Boehringer Ingelheim | 4 | $73 |
| Sanofi-aventis U.S. LLC | 3 | $62 |
| Braeburn Inc. | 3 | $57 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Merck | 3 | $45 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Cequr Corporation | 2 | $40 |
| Dexcom, Inc. | 2 | $39 |
| Harmony Biosciences LLC | 1 | $35 |
| Alnylam Pharmaceuticals Inc. | 2 | $29 |
| Kyowa Kirin, Inc. | 1 | $29 |
| Shield Therapeutics Inc | 2 | $28 |
| Alkermes, Inc. | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| TG Therapeutics, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Biogen | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Bayer | 1 | $14 |
| Hologic Sales And Service, LLC | 1 | $14 |
| Travere Therapeutics, Inc. | 2 | $11 |
How this compares
$2,741 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 272 | $223,692 |
| OzempicSemaglutide | 102 | $124,637 |
| JardianceEmpagliflozin | 87 | $92,466 |
| MounjaroTirzepatide | 66 | $72,522 |
| TrulicityDulaglutide | 39 | $37,805 |
| XareltoRivaroxaban | 43 | $36,806 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 50 | $36,529 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $20,093 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $13,292 |
| TradjentaLinagliptin | 11 | $12,576 |
| Atorvastatin Calcium | 774 | $8,935 |
| FarxigaDapagliflozin Propanediol | 21 | $7,882 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $7,612 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 34 | $6,967 |
| MyrbetriqMirabegron | 13 | $6,754 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $93 | $223,692272 claims |
| Novo NordiskOzempic | $295 | $124,637102 claims |
| Lilly USA, LLCMounjaro, Trulicity | $303 | $110,327105 claims |
| Boehringer IngelheimJardiance, Tradjenta | $73 | $105,04298 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $312 | $44,41171 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $353 | $39,20967 claims |
| Johnson & JohnsonXarelto | $18 | $36,80643 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $6,75413 claims |
| AbbVieSynthroid | $359 | $2,74858 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Williamsport
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.